Alternative Data for Sagimet Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 71 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 16 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,010 | Sign up | Sign up | Sign up |
| X Followers | 276 | Sign up | Sign up | Sign up |
| X Mentions | 7 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 24 | Sign up | Sign up | Sign up |
About Sagimet Biosciences
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways.
| Price | $5.21 |
| Target Price | Sign up |
| Volume | 348,330 |
| Market Cap | $169M |
| Year Range | $5.06 - $10.24 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdatesMarch 11 - GlobeNewswire |
|
Sagimet Biosciences Announces Participation in Three Upcoming Investor ConferencesFebruary 25 - GlobeNewswire |
|
 |
Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative SignalJanuary 29 - SeekingAlpha |
Biotech Veteran and Virologist Joins CancerVax as Senior Scientific AdvisorJanuary 27 - GlobeNewswire |
|
MASLD as a complication of obesity must include liver risk stratificationJanuary 6 - Nature.com |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -13M | -13M | -0.400 |
| Q2 '25 | 0 | 0 | 0 | -10M | -12M | -0.320 |
| Q1 '25 | 0 | 0 | 0 | -18M | -20M | -0.560 |
| Q4 '24 | 0 | 0 | 0 | -16M | -16M | -0.500 |
| Q3 '24 | 0 | 0 | 0 | -15M | -17M | -0.450 |
Insider Transactions View All
| Rozek Elizabeth filed to sell 190,959 shares at $5.4. February 12 '26 |
| Martins Eduardo Bruno filed to sell 103,296 shares at $5.4. February 12 '26 |
| Chauche Thierry filed to sell 15,688 shares at $5.4. February 12 '26 |
| Happel David filed to sell 677,621 shares at $5.4. February 12 '26 |
| Kemble George filed to sell 81,005 shares at $7.7. November 21 '25 |
Similar companies
Read more about Sagimet Biosciences (SGMT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Sagimet Biosciences
The Market Cap of Sagimet Biosciences is $169M.
Currently, the price of one share of Sagimet Biosciences stock is $5.21.
The SGMT stock price chart above provides a comprehensive visual representation of Sagimet Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Sagimet Biosciences shares. Our platform offers an up-to-date SGMT stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Sagimet Biosciences (SGMT) does not offer dividends to its shareholders. Investors interested in Sagimet Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Sagimet Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
